Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...
Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...
Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of Eylea (aflibercept 8mg, 114.3 ...
Investors were looking for a greater difference between Ocular’s experimental medicine and a low-dose version of Eylea, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Eylea HD improved vision with extended dosing intervals ...
TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Eylea for the treatment of retinopathy of prematurity in preterm infants, according to a press ...
The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results